These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20977291)

  • 1. Oligonucleotide delivery in cancer therapy.
    De Rosa G; De Stefano D; Galeone A
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1263-78. PubMed ID: 20977291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotide delivery to tumours using macromolecular carriers.
    Dass CR
    Biotechnol Appl Biochem; 2004 Oct; 40(Pt 2):113-22. PubMed ID: 15070400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide delivery: a cellular prospective.
    Liang E; Ajmani PS; Hughes JA
    Pharmazie; 1999 Aug; 54(8):559-66. PubMed ID: 10483609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer therapy via modulation of micro RNA levels: a promising future.
    Kota SK; Balasubramanian S
    Drug Discov Today; 2010 Sep; 15(17-18):733-40. PubMed ID: 20692360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review).
    Hope MJ; Mui B; Ansell S; Ahkong QF
    Mol Membr Biol; 1998; 15(1):1-14. PubMed ID: 9595549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FRET-FCS as a tool to evaluate the stability of oligonucleotide drugs after intracellular delivery.
    Remaut K; Lucas B; Braeckmans K; Sanders NN; De Smedt SC; Demeester J
    J Control Release; 2005 Mar; 103(1):259-71. PubMed ID: 15710516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NFkappaB decoy oligonucleotides.
    De Stefano D; De Rosa G; Carnuccio R
    Curr Opin Mol Ther; 2010 Apr; 12(2):203-13. PubMed ID: 20373264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool.
    Kaneda Y
    Expert Opin Drug Deliv; 2010 Sep; 7(9):1079-93. PubMed ID: 20716020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation.
    Scomparin A; Polyak D; Krivitsky A; Satchi-Fainaro R
    Biotechnol Adv; 2015 Nov; 33(6 Pt 3):1294-309. PubMed ID: 25916823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligonucleotide pharmacotherapy: an antigene strategy.
    Nagel KM; Holstad SG; Isenberg KE
    Pharmacotherapy; 1993; 13(3):177-88. PubMed ID: 8321732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence-defined polymers for the delivery of oligonucleotides.
    Lehto T; Wagner E
    Nanomedicine (Lond); 2014 Dec; 9(18):2843-59. PubMed ID: 25535686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of oncogenomics for cancer research and clinical oncology.
    Herrmann JL; Rastelli L; Burgess CE; Fernandez EE; Rothberg BE; Rothberg JM; Shimkets RA
    Cancer J; 2001; 7(1):40-51. PubMed ID: 11269647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleic acid therapeutic carriers with on-demand triggered release.
    Venkatesh S; Wower J; Byrne ME
    Bioconjug Chem; 2009 Sep; 20(9):1773-82. PubMed ID: 19670897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-targeted drug and gene delivery: principles and concepts.
    Cassidy J; Schätzlein AG
    Expert Rev Mol Med; 2004 Sep; 6(19):1-17. PubMed ID: 15387893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides.
    Hélène C
    Anticancer Drug Des; 1991 Dec; 6(6):569-84. PubMed ID: 1772570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery, Effect on Cell Viability, and Plasticity of Modified Aptamer Constructs.
    Gissberg O; Zaghloul EM; Lundin KE; Nguyen CH; Landras-Guetta C; Wengel J; Zain R; Smith CI
    Nucleic Acid Ther; 2016 Jun; 26(3):183-9. PubMed ID: 26859550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug delivery of oligonucleotides by peptides.
    Lochmann D; Jauk E; Zimmer A
    Eur J Pharm Biopharm; 2004 Sep; 58(2):237-51. PubMed ID: 15296952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.